Workshop on advancing proof-of-concept data in paediatric oncology drug development , Online, European Medicines Agency, Amsterdam, the Netherlands, from 21 September 2026, 13:00 (CEST) to 21 September 2026, 16:00 (CEST)

European Medicines Agency’s data protection notice for sharing contact details of network representatives in Agile teams via the restricted Network Portfolio website

Human medicines European public assessment report (EPAR): Feraccru, ferric maltol, Date of authorisation: 18/02/2016, Revision: 20, Status: Authorised

Human medicines European public assessment report (EPAR): Lojuxta, lomitapide, Date of authorisation: 31/07/2013, Revision: 21, Status: Authorised

Human medicines European public assessment report (EPAR): Constella, linaclotide, Date of authorisation: 26/11/2012, Revision: 32, Status: Authorised

Human medicines European public assessment report (EPAR): Trajenta, linagliptin, Date of authorisation: 23/08/2011, Revision: 24, Status: Authorised

Human medicines European public assessment report (EPAR): Skyrizi, risankizumab, Date of authorisation: 26/04/2019, Revision: 31, Status: Authorised

European Medicines Regulatory Network (EMRN) workshop on geographic atrophy endpoints, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, 29 April 2026

Human medicines European public assessment report (EPAR): Inaqovi, cedazuridine,decitabine, Date of authorisation: 15/09/2023, Revision: 4, Status: Authorised

EMEA-002451-PIP02-21

Human medicines European public assessment report (EPAR): Nintedanib Accord, nintedanib, Date of authorisation: 19/04/2024, Revision: 6, Status: Authorised

List of medicinal products under additional monitoring

List of medicinal products under additional monitoring

List of medicines under additional monitoring

HMA/EMA multistakeholder AI and Data forum: Build trustworthy AI on strong data foundations, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 12 November 2026 to 13 November 2026

PSUSA/00002633/202511

Human medicines European public assessment report (EPAR): Padcev, enfortumab vedotin, Date of authorisation: 13/04/2022, Revision: 8, Status: Authorised

Human medicines European public assessment report (EPAR): Tezspire, tezepelumab, Date of authorisation: 19/09/2022, Revision: 14, Status: Authorised

PSUSA/00009050/202511

Human medicines European public assessment report (EPAR): Cenrifki, tolebrutinib, Date of authorisation: 19/06/2026, Status: Authorised